Advertisement Continue reading the main story Supported by Continue reading the main story A Pill to Treat Covid-19? The U.S. Is Betting on It. A new $ 3.2 billion program will support the development of antiviral pills, which could start arriving by the end of this year. Video transcript Back bars 0:00/1:24 –0:00 transcript White… Read More »
In the three months since Johnson & Johnson’s COVID-19 vaccine received emergency use authorization from the U.S. Food and Drug Administration, more than 10 million Americans have received the vaccine, according to the Centers for Disease Control and Prevention. The single-shot viral vector vaccine — developed in collaboration with Beth Israel Deaconess Medical Center (BIDMC)… Read More »
CureVac’s late-stage COVID-19 vaccine trial flop clearly showed that not all pandemic shots are alike. But where does that leave the German biotech and its Big Pharma partners? For one, ongoing collaborations with Bayer and GlaxoSmithKline aren’t going anywhere for now, the companies said following the interim results drop late Wednesday. CureVac reported that its first-gen pandemic shot, known… Read More »
While work on COVID-19 vaccine boosters is already underway, one expert warned that emerging variants threaten to create a “window of susceptibility,” which without therapeutics could lead to more virus-inflicted death. “Of course there’s a need for boosters,” Dr. Jonathan Javitt, CEO of NRx and adjunct professor at Johns Hopkins School of Medicine, told Fox… Read More »